We are live on
!
Find out more
GA
Geneva Advisors Portfolio holdings
AUM
$5.81B
Turnover
22.5%
1-Year Est. Return
23.71%
This Fund
S&P 500
This Quarter
Est. Return
-6.12%
1 Year Est. Return
+23.71%
3 Year Est. Return
+53.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.96B
AUM Growth
-$641M
(-11%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
23.33%
Holding
765
New
46
Increased
242
Reduced
270
Closed
98
Avg Time Held
1.5
years
Top 10 Avg Time Held
0.9
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Manhattan Associates
MANH
|
+$33.6M |
| 2 |
Amazon
AMZN
|
+$32.3M |
| 3 |
CEB
CEB Inc.
CEB
|
+$27.7M |
| 4 |
Gilead Sciences
GILD
|
+$27.3M |
| 5 |
Merck
MRK
|
+$25.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$49.9M |
| 2 |
TWX
Time Warner Inc
TWX
|
+$30.5M |
| 3 |
Stericycle Inc
SRCL
|
+$29.3M |
| 4 |
Macquarie Infrastructure Holdings, LLC
MIC
|
+$25M |
| 5 |
Sunoco
SUN
|
+$21.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.16% |
| 2 | Financials | 16.84% |
| 3 | Consumer Discretionary | 14.26% |
| 4 | Technology | 13.32% |
| 5 | Industrials | 10.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
376
Alerian MLP ETF
AMLP
$12.6B
| $413K | 0.01% |
6,613
+1,090
| +20% | +$79.3K |
2013 Q2
9 quarters
|
|
377
Trimble
TRMB
$13.9B
| $411K | 0.01% |
25,004
-1,610
| -6% | -$32.5K |
2013 Q2
9 quarters
|
|
378
ScottsMiracle-Gro
SMG
$3.21B
| $405K | 0.01% |
6,655
-525
| -7% | -$32.4K |
2015 Q1
2 quarters
|
|
379
Intercontinental Exchange
ICE
$89.3B
| $404K | 0.01% |
8,605
-50
| -0.6% | -$2.31K |
2013 Q4
7 quarters
|
|
380
Eversource Energy
ES
$25.1B
| $394K | 0.01% |
7,792
+28
| +0.4% | +$1.35K |
2014 Q4
3 quarters
|
|
381
Raymond James Financial
RJF
$30.1B
| $385K | 0.01% |
11,643
| – | – |
2014 Q1
6 quarters
|
|
|
SQBK
382
DELISTED
SQUARE 1 FINANCIAL INC COM
SQBK
| $385K | 0.01% |
15,000
| – | – |
2014 Q2
5 quarters
|
|
|
PNY
383
DELISTED
PIEDMONT NATURAL GAS CO INC(NC
PNY
| $385K | 0.01% |
9,600
| – | – |
2013 Q2
9 quarters
|
|
384
iShares Dow Jones US ETF
IYY
$3B
| $382K | 0.01% |
7,926
-284
| -3% | -$14.5K |
2014 Q4
3 quarters
|
|
385
Compass Minerals
CMP
$941M
| $381K | 0.01% |
4,858
-523
| -10% | -$42.9K |
2014 Q4
3 quarters
|
|
386
CHS Inc Class B Series 4 Preferred Stock
CHSCL
$512M
| $371K | 0.01% |
14,000
| – | – |
2015 Q1
2 quarters
|
|
387
Controladora Vuela Compania de Aviacion
VLRS
$681M
| $370K | 0.01% |
+24,791
| New | +$341K |
2015 Q3
0 quarters
|
|
388
Credicorp
BAP
$30.9B
| $368K | 0.01% |
3,459
-557
| -14% | -$67.3K |
2014 Q1
6 quarters
|
|
389
American Water Works
AWK
$26.8B
| $367K | 0.01% |
6,661
-185
| -3% | -$9.67K |
2015 Q1
2 quarters
|
|
390
Exelon
EXC
$44.6B
| $367K | 0.01% |
17,340
-694
| -4% | -$15.6K |
2013 Q2
9 quarters
|
|
391
Ambev
ABEV
$50.4B
| $366K | 0.01% |
74,613
-12,245
| -14% | -$66.5K |
2013 Q4
7 quarters
|
|
392
DaVita
DVA
$12B
| $364K | 0.01% |
5,035
| – | – |
2014 Q1
6 quarters
|
|
|
PETX
393
DELISTED
Aratana Therapeutics, Inc.
PETX
| $364K | 0.01% |
43,074
+18,745
| +77% | +$317K |
2014 Q4
3 quarters
|
|
|
CDK
394
DELISTED
CDK Global, Inc.
CDK
| $360K | 0.01% |
7,528
+1,294
| +21% | +$65.7K |
2015 Q2
1 quarter
|
|
|
ETP
395
DELISTED
Energy Transfer Partners L.p.
ETP
| $359K | 0.01% |
8,741
+215
| +3% | +$10.4K |
2013 Q2
9 quarters
|
|
396
Vanguard FTSE All-World ex-US ETF
VEU
$67B
| $356K | 0.01% |
8,357
+1,820
| +28% | +$84K |
2013 Q4
7 quarters
|
|
397
Dr. Reddy's Laboratories
RDY
$10.8B
| $355K | 0.01% |
27,805
-11,015
| -28% | -$137K |
2015 Q1
2 quarters
|
|
398
DELISTED
Pioneer Natural Resource Co.
PXD
| $355K | 0.01% |
+2,922
| New | +$364K |
2015 Q3
0 quarters
|
|
399
ProShares Ultra QQQ
QLD
$14B
| $349K | 0.01% |
85,760
+38,400
| +81% | +$176K |
2015 Q2
1 quarter
|
|
|
GNMK
400
DELISTED
GenMark Diagnostics, Inc
GNMK
| $344K | 0.01% |
43,667
+19,037
| +77% | +$176K |
2014 Q4
3 quarters
|
|
Similar funds
CAM
DL
TCM
HCM
AL
AT
Geneva Advisors's Q3 2015 Portfolio in Review
As of Q3 2015, Geneva Advisors held 765 positions worth $4.96B, down 11% from $5.6B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Geneva Advisors withdrew a net $193M in Q3 2015, closing 98 positions and reducing 270 holdings. Its most notable exit was Potash Corp Of Saskatchewan, an estimated $21.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 19% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Geneva Advisors opened a new position in Alphabet (Google) Class A worth $15.8M.
- Geneva Advisors's largest Q3 2015 buy was Alphabet (Google) Class A: 496,420 shares worth $15.8M.
- Geneva Advisors added most to Manhattan Associates in Q3 2015, an estimated $33.6M increase.
- Geneva Advisors's biggest Q3 2015 reduction was Biogen, cutting an estimated $49.9M.
- Geneva Advisors fully exited Potash Corp Of Saskatchewan in Q3 2015, selling an estimated $21.6M.
- Geneva Advisors's ten largest holdings make up 23% of its $4.96B portfolio in Q3 2015.
- Geneva Advisors opened 46 new positions and closed 98 in Q3 2015.
- Geneva Advisors's portfolio value fell 11% quarter-over-quarter to $4.96B.
Based on Geneva Advisors's 13F filing for Q3 2015, filed 3 Nov 2015.